• Mashup Score: 0

    The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.In a complete response letter issued by FDA, the agency stated that it did not identify any clinical safety, study conduct, drug quality or manufacturing issues for

    Tweet Tweets with this article
    • ICYMI: @US_FDA rejected a supplemental new drug application for #patisiran to treat #cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness #Cardiotwitter https://t.co/Si0DgSOeQB

  • Mashup Score: 0

    The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.In a complete response letter issued by FDA, the agency stated that it did not identify any clinical safety, study conduct, drug quality or manufacturing issues for

    Tweet Tweets with this article
    • ICYMI: @US_FDA rejected a supplemental new drug application for #patisiran to treat #cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness #Cardiotwitter https://t.co/Si0DgSOeQB

  • Mashup Score: 11

    Abstract. Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adult

    Tweet Tweets with this article
    • Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic #cardiomyopathy ➡️ https://t.co/n838p7QFtA @ESC_Journals @ehj_ed @alessia_gimelli @EACVIPresident @ShehabAnwer @Sarah_Moharem @rafavidalperez @EZancanaroMD @EstefaniaOS @YevgeniyBr @echo_stepbystep… https://t.co/5C3mPTYskl https://t.co/xhDpnLoHco